Related Experiment Videos
Extracorporeal photochemotherapy: a scientific overview
1Department of Transfusion Medicine, City of Hope National Medical Center, Duarte, CA, USA.
Transfusion Science
|November 4, 1994
Summary
Extracorporeal photochemotherapy, using 8-methoxypsoralen (8-MOP) and UV light, shows clinical benefit for advanced cutaneous T-cell lymphoma (CTCL). Research is expanding to autoimmune diseases and transplant rejection, aiming to improve immune tolerance.
Area of Science:
- Dermatology
- Immunology
- Oncology
Background:
- Extracorporeal photochemotherapy (ECP) is a recognized treatment for cutaneous T-cell lymphoma (CTCL).
- ECP involves lymphapheresis with 8-methoxypsoralen (8-MOP) activated by ultraviolet (UV) light.
Purpose of the Study:
- To review the established and emerging applications of ECP.
- To highlight ongoing research in CTCL, autoimmune diseases, and transplant medicine.
Main Methods:
- Review of clinical trials and pilot studies involving ECP.
- Evaluation of ECP in combination therapies and new drug formulations.
- Comparison of ECP with conventional immunosuppressive therapies.
Main Results:
- ECP demonstrates clinical benefit in advanced CTCL.
- Emerging evidence suggests potential for ECP in autoimmune diseases and prevention of allograft rejection.
- ECP is being investigated for graft-versus-host disease following marrow transplantation.
Conclusions:
- ECP is a valuable therapeutic modality for CTCL.
- Further randomized studies are needed to confirm ECP's efficacy in autoimmune diseases, organ transplantation, and graft-versus-host disease.